Predictive Factors of the Adherence to Real-Time Continuous Glucose Monitoring Sensors: A Prospective Observational Study (PARCS STUDY).
CGM
CSII
HFS
PAID
QOL
adherence
Journal
Journal of diabetes science and technology
ISSN: 1932-2968
Titre abrégé: J Diabetes Sci Technol
Pays: United States
ID NLM: 101306166
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
pubmed:
9
8
2020
medline:
3
11
2021
entrez:
9
8
2020
Statut:
ppublish
Résumé
Information about factors related to better adherence to continuous glucose monitoring (CGM) sensor adherence is quite limited. Forty-six participants with type 1 diabetes using continuous subcutaneous insulin infusion (CSII) without CGM were recruited. The participants' characteristics and diabetes-related quality of life (QOL) were evaluated at baseline and one year after starting to use CGM. Participants wearing the sensor for ≥60% of the time were considered as adherent. The mean age of the 46 participants was 44.1 ± 15.0 years old and the mean glycohemoglobin (HbA1c) was 7.7 ± 1.0%; 60.9% of the participants were classified as adherent. The duration of using CSII was longer in the adherent group, and the degree of diabetic retinopathy was significantly different. There were no significant differences in age, frequency of self-monitoring of blood glucose, or Hypoglycemia Fear Survey (HFS-B for behavior, HFS-W for worry) score at baseline between the adherent and nonadherent groups. The Problem Areas in Diabetes (PAID) score at baseline was significantly higher and the total CSII-QOL score at baseline was significantly lower in the adherent group. The usage of dual-wave bolus was significantly increased in the adherent group (34.6%-61.5%, Higher adherence to CGM sensors may be associated with a heavier emotional burden of diabetes and a worse QOL in relation to CSII at baseline.
Sections du résumé
BACKGROUND
Information about factors related to better adherence to continuous glucose monitoring (CGM) sensor adherence is quite limited.
MATERIALS AND METHODS
Forty-six participants with type 1 diabetes using continuous subcutaneous insulin infusion (CSII) without CGM were recruited. The participants' characteristics and diabetes-related quality of life (QOL) were evaluated at baseline and one year after starting to use CGM. Participants wearing the sensor for ≥60% of the time were considered as adherent.
RESULTS
The mean age of the 46 participants was 44.1 ± 15.0 years old and the mean glycohemoglobin (HbA1c) was 7.7 ± 1.0%; 60.9% of the participants were classified as adherent. The duration of using CSII was longer in the adherent group, and the degree of diabetic retinopathy was significantly different. There were no significant differences in age, frequency of self-monitoring of blood glucose, or Hypoglycemia Fear Survey (HFS-B for behavior, HFS-W for worry) score at baseline between the adherent and nonadherent groups. The Problem Areas in Diabetes (PAID) score at baseline was significantly higher and the total CSII-QOL score at baseline was significantly lower in the adherent group. The usage of dual-wave bolus was significantly increased in the adherent group (34.6%-61.5%,
CONCLUSIONS
Higher adherence to CGM sensors may be associated with a heavier emotional burden of diabetes and a worse QOL in relation to CSII at baseline.
Identifiants
pubmed: 32762345
doi: 10.1177/1932296820939204
pmc: PMC8442175
doi:
Substances chimiques
Blood Glucose
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
Insulin
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1084-1092Références
N Engl J Med. 1993 Sep 30;329(14):977-86
pubmed: 8366922
Diabetologia. 2012 Dec;55(12):3155-62
pubmed: 22965294
J Clin Endocrinol Metab. 2018 Mar 1;103(3):1224-1232
pubmed: 29342264
N Engl J Med. 2008 Oct 2;359(14):1464-76
pubmed: 18779236
J Diabetes Sci Technol. 2017 Sep;11(5):1055-1056
pubmed: 28859515
Diabetes Care. 2009 Nov;32(11):1947-53
pubmed: 19675206
Diabetes Technol Ther. 2016 Feb;18 Suppl 2:S3-S13
pubmed: 26784127
J Diabetes Investig. 2010 Oct 19;1(5):212-28
pubmed: 24843435
Diabetes Care. 2017 Jun;40(6):736-741
pubmed: 28389582
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Diabetes Care. 2010 Oct;33(10):2175-7
pubmed: 20696865
N Engl J Med. 2010 Jul 22;363(4):311-20
pubmed: 20587585
Qual Life Res. 2016 Mar;25(3):707-19
pubmed: 26303761
Diabetes Technol Ther. 2020 Mar;22(3):216-221
pubmed: 31638420
Diabetes Care. 2011 Apr;34(4):801-6
pubmed: 21346182
Diabetologia. 2006 May;49(5):828-36
pubmed: 16568259
Lancet. 2018 Apr 7;391(10128):1367-1377
pubmed: 29459019
J Diabetes Investig. 2015 Nov;6(6):687-91
pubmed: 26543543
Diabetes Care. 1997 May;20(5):760-6
pubmed: 9135939